Mara Aspinall

Managing Director

Aspinall is a healthcare industry leader and pioneer with a commitment to active civic involvement. Aspinall is Co-Founder and Managing Director of BlueStone Venture Partners LLC.  BlueStone, a premier venture firm investing in life sciences based technology and innovation companies in the US Southwest.  Aspinall is also CEO of Health Catalysts Group, a firm dedicated to the growth of new healthcare companies. The firm’s focus is health information technology and diagnostics firms, publishing the popular Health Catalysts Diagnostics Year in Review.  

Aspinall is a member of the Board of Directors of Allscripts (MDRX), Orasure (OSUR), Abcam plc (ABC), 3Scan, Blue Cross Blue Shield Arizona and Castle Biosciences.

Aspinall is the former President and CEO of Ventana Medical Systems, a billion-dollar division of The Roche Group, worldwide leader in development and commercialization of tissue-based cancer diagnostics and digital imaging. At Ventana, with her world-class team, she led the company to new financial success, more than two dozen major instrument and assay launches and global leadership in companion diagnostics.

Previously, Aspinall spent 12 years with Genzyme Corporation as President of Genzyme Genetics and Genzyme Pharmaceuticals. Genzyme Genetics, grew to become the country’s leading diagnostic testing company, was sold to LabCorp for $1 billion in 2010. Aspinall was also Founder and CEO of On-Q-ity, a start-up diagnostic company dedicated to circulating tumor cells.

Aspinall has spearheaded initiatives to educate payers and policymakers on genomics and personalized medicine. She served as an active member of the Health and Human Services Secretary’s Advisory Council on Genetics, Health & Society (SACGHS) in both the Obama and Bush administrations. Aspinall was also a Trustee of the Dana Farber Cancer Institute for 11 years, where she chaired the Trustee Science Committee.

With a passion for education about the importance of diagnostics in healthcare, Aspinall co-founded the International School of Biomedical Diagnostics at Arizona State University, the first and only program dedicated entirely to Diagnostics as an independent discipline. ASU awarded their first Master degrees in Diagnostics in 2015 and has 102 Master’s students matriculating this year.

Aspinall is a frequent national speaker on healthcare related issues. She was named Arizona Biosciences Leader of the Year in 2016 by the Arizona Biotechnology Association and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine.

Mara started her business career at the strategic consulting firm Bain & Company. She holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.